Evidence map›Paper›PMID 30861005›Full record

ArticlePloS one2019

Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.

Jenny L Wilkerson, David R Schulze, Lance R McMahon

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.The Journal of pharmacology and experimental therapeutics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jenny L WilkersonDepartment of Pharmacodynamics, The University of Florida, College of Pharmacy, Gainesville, Florida, United States of America.ORCID 0000-0002-5594-061X
David R SchulzeDepartment of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America.
Lance R McMahonDepartment of Pharmacodynamics, The University of Florida, College of Pharmacy, Gainesville, Florida, United States of America.ORCID 0000-0003-0360-6318
The University of Texas Health Science Center at San Antonio · USUniversity of Florida · US

Funding

Opioid use disorders: UF Pharmacy medications discovery and developmentUH3DA048353 · NIDA · UNIVERSITY OF FLORIDA · PI MCCURDY, CHRISTOPHER R, MCMAHON, LANCE R. · 2021 to 2023
$4.5M
Opioid use disorders: UF Pharmacy medications discovery and developmentUG3DA048353 · NIDA · UNIVERSITY OF FLORIDA · PI MCCURDY, CHRISTOPHER R, MCMAHON, LANCE R. · 2019 to 2020
$3.6M
Nicotine dependence: neuropharmacology in monkeysR01DA025267 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MCMAHON, LANCE R. · 2009 to 2018
$3.4M
NIDA NIH HHS R01 DA025267NIDA NIH HHS UG3 DA048353NIDA NIH HHS UH3 DA048353
6 · The paper itself

Abstract

Cannabis withdrawal upon discontinuation of long-term, heavy Cannabis use is reported in humans; however, methods to establish the nature and intensity of cannabinoid withdrawal, especially directly observable signs, have not been widely established. This study quantified activity in the home cage of rhesus monkeys and examined the extent to which activity can be used to quantify tolerance to and dependence on Δ9-tetrahydrocannabinol (Δ9-THC). Home-cage activity was measured in one group that received Δ9-THC (1 mg/kg s.c.) every 12 h (i.e., chronic Δ9-THC), and a second group that received Δ9-THC (0.1 mg/kg i.v.) once every 3 days (i.e., intermittent Δ9-THC). Treatment was temporarily discontinued in the chronic Δ9-THC group and the effects of rimonabant and Δ9-THC were examined in both groups. Activity counts were highest during the day (lights on 0600-2000 h) and were lower at night. Rimonabant (0.1-3.2 mg/kg i.v.) dose-dependently increased activity (maximum 20-fold) in the chronic Δ9-THC group but did not significantly alter activity in the intermittent Δ9-THC group. Δ9-THC (0.32-3.2 mg/kg i.v.) dose-dependently decreased activity counts (maximum 4-fold) in both groups but was somewhat more potent in the intermittent as compared with the Δ9-THC group. Discontinuation of Δ9-THC treatment resulted in an immediate (i.e., within 24 h) and time-related increase in activity. The time-related increase in home-cage activity upon abrupt discontinuation of chronic Δ9-THC treatment, as well as the effects of rimonabant to increase activity in monkeys receiving chronic, but not intermittent, Δ9-THC treatment, are consistent with signs of physical dependence on Δ9-THC in primates.

Indexed as

Drug ToleranceAdministration, IntravenousAnimalsDisease Models, AnimalDronabinolFemaleHallucinogensHumansMacaca mulattaMaleMotor ActivityRimonabantSubstance Withdrawal SyndromeDronabinolHallucinogensRimonabant

Identifiers

PMID30861005
PMCPMC6413903
OpenAlexW2951414256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.